Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

4Total
P 1 (4)

Trial Status

Active Not Recruiting2
Terminated1
Enrolling By Invitation1

Clinical Trials (4)

Showing 4 of 4 trials
NCT06193174Phase 1Terminated

Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)

NCT06614855Phase 1Active Not Recruiting

A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma

NCT03657576Phase 1Active Not Recruiting

Trial of C134 in Patients With Recurrent GBM

NCT06896110Phase 1Enrolling By Invitation

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

Showing all 4 trials

Research Network

Activity Timeline